Neurobiol Aging 2019;75:159-68
No pharmaceutical company, no academic medical center, and no government agency has found the existing preclinical data compelling enough to fund a rigorous human trial in over 30 years
So to see studies like these supporting
This type of cochlear synaptopathy, referred to as hidden hearing loss because the deficits can hide behind a normal audiogram 11 , is posited to trigger neural hyperactivity that underlies tinnitus 19,20,21 , potentially offering a valuable drug target for the development of novel tinnitus treatments
If a patient is asking about GLP-1/GIP medicines, direct them to a conversation with their prescriber and share neutral background reading on those medicines from peer-reviewed journals
Reduction of the elastase inhibitory capacity of alpha 1-antitrypsin by peroxides in cigarette smoke: an analysis of brands and filters